Matro R, et al. - A multi-center prospective study was performed to examine whether biologics are detectable in breast milk from women receiving treatment for inflammatory bowel diseases (IBD) and whether breastfeeding while on treatment is linked with infections or developmental delays. Low concentrations of infliximab, adalimumab, certolizumab, natalizumab, and ustekinumab in breast milk samples was detected in a study of women receiving treatment for IBD and their infants. They discovered breastfed infants of mothers on biologics, immunomodulators, or combination therapies to have similar risks of infection and rate of milestone achievement compared to non-breastfed or infants unexposed to these drugs. Data reported that maternal use of biologic therapy seems compatible with breastfeeding.